Equest Pramox 19.5 mg/g + 121.7 mg/g Oral Gel

Care should be taken to avoid the following practices, because they increase the risk of
development of resistance and could ultimately result in ineffective therapy:
- Too frequent and repeated use of anthelmintics from the same class, over an
extended period of time;
- Under-dosing which may due to underestimation of body weight, misadministration of
the product, or lack of calibration of the dosing device (If any).
- Suspected clinical cases of resistance to anthelmintics should be further investigated
using appropriate tests (e.g. Faecal Egg Count Reduction Test). Where the results of
the test(s) strongly suggest resistance to a particular anthelmintic, an anthelmintic
belonging to another pharmacological class and having a different mode of action
should be used.
For optimum control of bots, the veterinary medicinal product should be administered in
the autumn, after the end of the fly season and before spring as the larvae may start to
pupate and therefore are less sensitive to treatment.
Parasite resistance to a particular class of anthelmintic may develop following frequent,
repeated use of an anthelmintic of that class. The veterinarian should give advice regarding
appropriate dosing programmes and stock management to achieve adequate parasite control
for both tapeworm and roundworm infestations.

Special precautions for use in animals
To avoid overdosing, care should be taken to accurately dose foals, especially low body
weight foals or pony foals.
Do not use the same syringe to treat more than one animal unless horses are running
together or in direct contact with each other in the same premises.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
This veterinary medicinal product may cause eye irritation, skin irritation and skin
sensitisation.
Avoid contact with skin and eyes.
Personal protective equipment consisting of protective gloves should be worn when
handling the veterinary medicinal product.
Wash hands or any exposed area after use.
Do not smoke, drink or eat while handling the veterinary medicinal product.

Amended pages: March 2025
AN: 02770/2023
In case of eye contact, flush the eye with copious amounts of clean water and seek
medical advice immediately and show the package leaflet or the label to the physician.
In case of accidental ingestion, seek medical advice immediately and show the package
leaflet or the label to the physician.
Special precautions for the protection of the environment
Moxidectin fulfils the criteria for a (very) persistent, bioaccumulative and toxic (PBT)
substance; therefore, exposure of the environment to moxidectin must be limited to the
extent possible. Treatments should be administered only when necessary and should be
based on faecal egg counts or evaluation of the risk of infestation at the animal and/or
herd level. In order to reduce the emission of moxidectin to surface water and based on
the excretion profile of moxidectin when administered as the oral formulation to horses,
treated animals should not have access to watercourses during the first week after
treatment.
Like other macrocyclic lactones, moxidectin has the potential to adversely affect non-target
organisms:
•
reduce the abundance of dung feeding organisms. Following treatment of horses with
the veterinary medicinal product, levels of moxidectin that are potentially toxic to dung
beetles and flies may be excreted over a period of more than 1 week and may decrease
dung fauna abundance.
•
medicinal product should be used only according to the label instructions.
In order to limit the impact of moxidectin on dung fauna, and due to insufficient data
regarding environmental risk of praziquantel, horses should not be turned out onto pasture
within 3 days of treatment.
Other precautions
Not applicable.